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Background
Cancer represents a broad group of various diseases, all involving unregulated and progressive cell growth. Collectively they account for approximately 13% of all deaths each year worldwide.
1 Camptothecin (CPT), an alkaloid extract from plants known as Camptotheca acuminata, exhibits an anti-cancer activity against several types of cancer cells and animal tumor models due, at least in part, to the inhibition of DNA topoisomerase I (Topo-1) and resulting cell death. [2] [3] [4] Topo-1 remains a highly attractive drug target because it is essential for basic cellular processes including DNA replication, recombination and transcription. It is particularly up-regulated in rapidly dividing tumor cells. 5 CPT inhibits the resealing of single-strand DNA breaks mediated by Topo-1.
CPT is not used clinically because of its poor solubility and high systemic toxicity. In particular at physiologic pH, the active lactone ring of CPT hydrolyzes to yield the inactive carboxylate form that strongly binds to serum albumin, resulting in further driving the reaction towards the inactive form. 3 camptothecin (CPT) and a cyclodextrin-based polymer. 7 In CRLX101, CPT is linked covalently through a glycine linker to the linear copolymer CDP, which in turn consists of alternating subunits of beta-cyclodextrin and polyethylene glycol (PEG). 7 Conjugation of CPT to CDP increases the aqueous solubility of active CPT by three orders of
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4 magnitude over native CPT and prevents inactivation through spontaneous lactone ring opening at physiologic pH. CRLX101 is preferentially accumulated in tumors due to leaky vasculature known as enhanced permeability and retention (EPR) effect, and slowly released inside tumor cells as the linkage is hydrolyzed, thereby reducing systemic exposure and the subsequent toxic side effects. 8, 9 Preclinical studies have shown that sustained release of active CPT from CRLX101 nanoparticles results in extended Topo-1
and HIF-1α inhibition, thus increasing antitumor efficacy, as compared to standard dosing for irinotecan or topotecan. 8, [10] [11] [12] [13] [14] Results from several studies have shown presence of CRLX101 as intact nanoparticles in tumor sections from both animals and patients. 11, 13, 15, 16 Human cancers are characterized by intratumoral hypoxia that results from deregulated cell proliferation. Physiological responses triggered by hypoxia affect all critical aspects of cancer progression, including immortalization, transformation, differentiation, genetic stability, angiogenesis, invasion, metastasis, treatment outcome and resistance to therapy. 17 Expression of carbonic anhydrase IX (CaIX), a member of the carbonic anhydrase family that catalyzes the reversible hydration of carbon dioxide to carbonic acid, is directly driven by hypoxia inducible factor-1 (HIF-1). 18 This gene product is expressed in many types of human cancers and is usually absent in their normal counterparts and is linked with poor prognosis in several tumor types. 18, 19 Camptothecin and its analogs have been reported to function by not only inhibiting HIF-1α transcriptional activity but also protein accumulation. 20 HIF-1α is known to upregulate genes involved in a variety of processes, including angiogenesis. 19 Vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) have been examined widely as biomarkers for angiogenesis and are shown to correlate with stage, grade and prognosis of patients. 21, 22 A significant decrease in expressions of Ki-67, CaIX,
VEGF, and CD31 proteins in CRLX101 treated tumors was also observed in mice by immunohistochemistry (IHC) indicating an inhibition of proliferation, HIF-1 and angiogenesis.
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Another challenge of the present day clinical research is to assess the least toxic and most effective therapy for a specific patient because of the genetic variations encoding for metabolizing enzymes and drug transporters, which have been demonstrated to affect interindividual drug responses by alteration of absorption, distribution, metabolism and elimination (ADME). 23 The Affymetrix Drug Metabolism Enzymes and Transporters (DMET) microarray is the first assay enabling the simultaneous genotyping of a large number of known markers (1,936 markers in 225 genes) in drug ADME. 
CRLX101 is currently under investigation in several human trials (Clinical

Patient selection and study design
Patients included in the study were ≥ 18 years old with histologically or cytologically confirmed metastatic or unresectable solid tumor malignancies refractory to standard curative therapy. Additional eligibility requirements were as described in Weiss et al. 16 
Tissue preparation and immunohistochemical staining
The immunohistochemical assays were performed using a Dako Autostainer Plus (Dako Colorado Inc., CO) with fresh sections of tumor biopsy tissue removed before and/or after the treatment as described in . Antigen detection was accomplished using the vectastain elite ABC goat HRP kit (Vector labs, CA). The sections were counterstained with Meyer's hematoxylin and each run also included phosphate buffered saline (PBS) replacing the primary antibody for the negative controls, whereas samples known to express Topo-1, Ki-67, CaIX, VEGF, or CD31 served as positive controls. Photomicrographs were taken on a Nikon microscope equipped with a CCD camera (QImaging, Canada). Expression of proteins was quantified using a visual grading (0-no staining to 3-maximum staining) system on the basis of the extent of staining intensity (e.g., integrated optical density), and/or percentage of stained cells (e.g., total area or percentage of cells positive) for each image.
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RNA extraction and quantitative reverse transcription-PCR (RT-PCR)
Peripheral blood was drawn in PAXgene tubes and total cellular RNA was isolated from whole blood using the PAXgene Blood RNA kit (Qiagen, CA). On-column
DNaseI digestion was performed during RNA purification to remove Genomic DNA contamination. The RNA concentration and A260:A280 ratio was measured using a Nanodrop spectrophotometer (NanoDrop Technologies Inc., DE). 
Statistical Analysis:
Graph Pad Prism 6.0 was used for statistical analysis and figure drawing. Group comparisons were performed using Student's t-test or two-way ANOVA and mean±standard error of the mean were used to present continuous variables. A p-value <0.05 was considered statistically significant. Kaplan-Meier analysis was applied to overall survival analysis. The Pearson's correlation coefficient analyzed the association between quantitative variables.
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Results
Clinical characteristics and administered dosage of CRLX101 in patients included in study are summarized in Table S1 .
CRLX101 inhibits topoisomerase expression
We checked the expression level of Topo-1 in pre-and post-CRLX101-treated skin biopsy samples from a triple negative breast cancer patient. The pre-treatment biopsy sample was collected 3 days prior to the start of first cycle while the posttreatment sample was collected 3 days after the day 15 infusion of cycle 2 of CRLX101 CaIX, which is associated with dysplasia and malignant tumors showed a higher expression of (100% cells positive for CaIX) in the pretreated section Figure 2A (ii) as compared to the CRLX101 post-treatment tumor section Figure 2B (ii).
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Since angiogenesis is crucial for tumor development, CD31 has been widely used as a marker to highlight the density of intratumoral vessels and the degree of Although, the average staining intensity score for Topo-1, Ki-67, CaIX and CD31 was also higher in group 1 as compared to group 2 ( Figure 3B , i-v), it was significantly (p<0.05) different for only Topo-1 and Ki-67 expression. The expression of all the proteins was inversely proportional to survival duration of the patients ( Figure 3C , i-v).
The expression score for Ki-67 was best correlated (p<0.01), followed by Topo-1 and CaIX being next (p=0.01) respectively. The expression of CD31 and VEGF correlated the least with the survival time (p<0.05 and p=0.27). The expression score for Ki-67 when combined with another variable such as either of CaIX, CD31 or Topo-1 resulted in a significant increase in the correlation coefficient (p<0.01) respectively with survival time.
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These data suggest that the combined score of two variables may be used for predicting the outcome of the treatment.
Plasma Cytokine and Platelet Levels
Elevated plasma cytokine levels have been reported in different types of cancers and sometimes correlated with increased side effects of the treatment and disease progression. There is a burgeoning amount of evidence, particularly in breast and prostate cancer, that markers of increased immune inflammatory activity are associated with fatigue. 24 Although the clinical meanings of the relationships is not yet known, the increase in levels of cytokines likely contributes to the symptoms of asthenia, fatigue and lethargy, as supported by cytokine-induced sickness behavior in animal models and humans. 25, 26 The most common CRLX101 related adverse effect in patients included fatigue, anemia, neutropenia, leucopenia and thrombocytopenia. To better understand causes of fatigue, we assessed plasma cytokine levels (listed in Figure 4 ) prior to treatment and on day 8 of cycle 1 of CRLX101 treatment. Majority of these cytokines were already at levels several fold higher than the normal range in all the patients and mean plasma levels of most of these cytokines increased further although not significant, with CRLX101 treatment. The survival duration was longer for patients with lower IL levels as compared to the patients with shorter survival duration (Table S2 ). Our results showed that IL2R, the receptor for IL-2 levels expression was almost 2X higher for group 1 than group 2 (715±138 vs 350±50pg/ml, p<0.05). This is in agreement with a report showing a significantly higher IL2R expression in late stage lung cancer as compared to early stage colorectal cancer. 27 Similarly, expression for IL-8 was several folds higher for the group 1 compared to group 2 (164±96 vs 30±5pg/ml). Although not significant, this level increased further after CRLX101 treatment in group 1 while decreasing in group 2.
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These results are supported by a study an in vivo tumorigenesis analysis in pancreatic cancer showing that tumor tissues from patients with higher serum IL-8 levels grew faster than those with lower IL-8 levels. 28 The levels of MIP-1a and MCP-1 were higher in the longer surviving group and increased further after CRLX101 treatment. IFN- also increased after CRLX-101 treatment. Additionally, while not statistically significant, only IL-1Ra, IL-10 and IL-12p40/p70 values were reduced after CRLX101 treatment. In patients having an adverse event (AE) grade of ≥ 3, higher percentage change in plasma cytokine levels were observed when compared to a patient with an AE of grade 1 ( Figure   4A ). Among all patients with AE of grade 3, only one patient was from the longer survival group. Our results are in agreement with previous reports shown in patients with breast and prostate cancer. 24, 29 Other studies have also shown that high innate production capacity of proinflammatory cytokines is associated with increased tumor burden, aggressiveness and metastasis. 30, 31 Additionally, analysis of patient blood samples revealed that mean platelet counts were transiently decreased, on day 14 of cycle 1 compared with pre-treatment levels. This decrease was significant only in group 1 patients whose survival duration was shorter than 6 months (p = .034, Figure 4B ). Platelet aggregation was also observed in some cases; however, neither the platelet number nor aggregation of platelets was associated with clotting or excessive bleeding in any patient. A significant decrease in hemoglobin in group 1 compared to group 2 (15% vs 3.5%) may also account for fatigue (p= 0.05, Figure 4C ). Portenoy and Itri demonstrated an association between chemotherapyinduced mild-to-moderate anemia and both fatigue and quality-of-life impairment. They also showed that patients with an increase in hematocrit of >6% also demonstrated significant improvement in energy level and daily activities.
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Response and genotyping analysis
To exclude the possibility that the lower toxicity observed in these patients might be due to allele frequency difference in SNPs of drug metabolism genes, we compared the allele frequencies between the patient cohort in the current study (n=8, Group 1 and n=7, Group 2) and the global population data obtained from Affymetrix, which included 713 HapMap samples consisting of individuals from various descent. Figure 5A indicates that the frequencies of the alleles on DMET array in these patients are very similar to those of the population (Chi Square test p > 0.05). The enzyme activity of genes on the DMET array was also categorized with Affymetrix's Genotyping Console, and the association of these enzymes with toxicity and response phenotype was examined. Using
Fisher's exact test (P<0.01), 157 SNPs were identified as having different allele frequency in patients compared to the general population. However, none of these SNPs were found to be associated with either toxicity phenotype or response status. The only SNP found to be overlapping with response association was a non-synonymous SNP in flavin containing mono-oxygenase 2 (FMO2) ( Figure 5B ). Although the sample size is small, these results suggest the observed lower toxicity in these patients was not likely due to different genotypes in these DMET SNPs. These results indicate that the lower toxicity in the current patient cohort is not due to allele frequency difference in drug metabolism genes.
Discussion
Numerous preclinical and clinical studies have demonstrated that treatment with
Topo-1 inhibitors result in tumor regression. 6, 11, 33, 34 It has also been suggested that the cytotoxic effects of these inhibitors are dependent on the stabilization of topoisomerase-DNA complex. 35 Both in vitro and in vivo studies have demonstrated that sensitivity to these agents is modulated by absolute value of Topo-1 levels and Topo-1 protein expression is correlated well with poor patient survival. Our results showed a significant decrease in the expression of Topo-1 in post treatment sections. This is in agreement with other studies showing a decrease in expression and activity of Topo-1 after treatment with camptothecin or its analogs. 16, 35 Our results also showed significantly decreased expression of Topo-1 in patients with longer survival duration as compared to the group with shorter survival duration. These results are not supported by the earlier hypothesis that lower expression of Topo-1 is correlated with a worse response to Topo-1 inhibitors. 36, 37 However, results of other studies from Dutch colorectal cancer group failed to replicate the findings and concluded that although absolute Topo-1 expression may play a role, it is likely that additional pathways contribute to irinotecan sensitivity of Topo-1. 38, 39 Therefore, these results indicate that clinical significance of Topo-1 is still unknown and remains controversial as prognostic marker.
Our results showed a decrease in expression of Ki-67 post-CRLX101 treatment.
Also, the expression of Ki-67 was higher in the tumor section of a patient who survived for 3 months as compared to the one with a longer survival time (27 months). Our results are in agreement with studies that suggested a positive correlation between Ki-67 score and shorter survival. 40, 41 We have previously shown that CRLX101 treatment inhibited expression of CaIX in a tumor sections. Also the expression of CaIX was lower in the sample from the patient with longer survival duration as compared to the other. However,
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mRNA expression of HIF-1 showed insignificant difference before and after treatment (data not shown). These results are consistent with earlier reports of inhibition of hypoxia by camptothecin analogs. 11, 42, 43 HIF-1α is known to upregulate genes involved in a variety of processes such as angiogenesis.
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VEGF and CD31 have been examined widely as biomarkers for angiogenesis and are shown to correlate with stage, grade, and prognosis of patients. 21, 22 Our results showed a decrease in expression of VEGF and CD31 (microvessel density) in the post-treatment tissue sample. Also, the tissue from the patient with a shorter duration of survival had stronger expression of both the proteins as compared to the tissue from the longer surviving patient. Therefore, we conclude that expression of Ki-67, CaIX, CD31 and VEGF are inversely proportional to patient's survival duration. These results are consistent with previous reports that increased proliferation, positive expression of HIF-1 and VEGF are associated with shorter disease-free survival and overall survival in patients with gastric cancer. 40, 44 High incidence of gastrointestinal toxicity, hemorrhagic cystisis and severe bone marrow suppression in early clinical trials dampened the usage of CPT and encouraged the development of CPT analogs . 45 Two less potent small molecule derivatives (topotecan and irinotecan) achieved notable improvement over CPT but are still not well tolerated. 46 Our phase 1/2a result showed CRLX101-related adverse events including fatigue, cystitis, anemia, neutropenia, leucopenia and thrombocytopenia in some patients, but these events have been far less in severity as compared to CPT or its derivatives. 16 The levels of most common interleukins increased after treatment with CRLX101; however, they were lower in the group whose survival time was longer than 6 months suggesting that secretion of cytokines might be used as a tool to monitor the therapeutic indices of the drug. Also, higher levels of MIP-1a in the longer surviving group and its increase after treatment with CRLX101 in both groups is in agreement with the report
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18 that tumor cells transfected with the MIP-1a gene might be useful as an effective therapy for the treatment of certain tumors. 47 Low serum MCP-1 levels have been identified in patients with worse prognosis similar to that reported in the current study. Interferon has been shown to facilitate anti-tumor activity by promoting antigen presenting cell mediated expansion of cytotoxic T cells and activating macrophages to release molecules such as superoxide. 48 Our results also show an increase in IFN- levels after CRLX-101 treatment. A phase Ib study of the hepatocyte growth factor (HGF)-inhibitor AMG-102 in combination with either bevacizumab or motesanib identified post-treatment elevation in HGF levels which coincided with a 75% increase in all grades of fatigue, similar to those reported in the current study. 49 This data suggests that high innate production capacity of proinflammatory cytokines is associated with shorter survival, probably because of increased tumor growth and metastasis. A significant decrease in platelet counts and hemoglobin by day 14 of the first treatment cycle may provide a possible mechanism for treatment-related fatigue; however, additional studies are needed to clarify the relationship.
The DMET array enables a cost-effective measurement of existing and new metabolic pathway involvement by providing broad coverage of relevant pharmacogenetic markers in one assay. However, due to the small sample size, the chisquare p value was not significant for the patient group and a larger cohort should be used to validate these results.
In summary, these results reinforce the statement of the importance of CRLX101 as a promoter of increased anti-tumor activity in patients with solid tumor malignancies.
These results also confirm that the possible mechanistic rationale for treatment with CRLX101 in the patients is inhibition of proliferation, hypoxia and angiogenesis
19 correlating with slow tumor growth presumably due to lack of survival factors supplied through blood and therefore longer survival time. 
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